AIM ImmunoTech Announces First Dose Level is Generally
Next safety cohort to begin escalated dosing soon...
Source: globenewswire.com
Page 23 - Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Solid Tumors Today - Breaking & Trending Today
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
ENHERTU demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of...
Source: marketscreener.com
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients with HER2 ultralow expression Plans for global regulatory...
Source: marketscreener.com
A New Weapon Against Cancer: Checkpoint Inhibitors, A Double-Edged Sword
Checkpoint inhibitors, a novel class of anticancer medications, embrace a unique approach to counter tumors.
Source: forbes.com
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer | Company Announcement
Investegate announcements from AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Source: investegate.co.uk